Influence of hysterectomy on the fibrinolytic activity of plasma of women with intact ovarian function.
Hysterectomies are frequently required operations in gynecology. Several studies have reported an association between premenopausal hysterectomy and the risk of cardiovascular diseases. However, the pathophysiological linkages between these two conditions have not been elucidated. In recent years it has been shown that a decrease in plasma fibrinolytic activity is associated with increased risk of thrombosis. Furthermore, it has been known that the uterus is a very finbrinolytic active organ. In the present study we investigated the hypothesis that hysterectomy may lead to a decrease in plasma fibrinolytic activity, and thereby increase the risk for thromboembolic diseases. Fibrinolytic parameters of plasma were investigated in 26 women before and 6 weeks after premenopausal hysterectomy. Euglobulin lysis time (ELT), a global measure of plasma fibrinolytic activity, and the levels of tissue plasminogen activator (tPA) and plasminogen activator inhibitor type 1 (PAI-1) were not different before and after hysterectomy. The ELT difference before and after venous occlusion, which is a good indicator for the risk of thrombosis, was also not significantly changed after hysterectomy. Estradiol-17 beta, progesterone, LH, FSH and sex hormone binding globulin displayed no significant changes after hysterectomy. Furthermore, the hormone measurements also indicated that the women were premenopausal. There were no correlations between the hormone values and fibrinolytic parameters. These data indicate that premenopausal hysterectomy does not lead to changes in plasma fibrinolytic activity.
Schubring
C
C
Department of Gynaecology and Obstetrics, Evangelisches Krankenhaus Giessen, Germany.
Grulich-Henn
J
J
Bauer
S
S
Gips
H
H
Müller-Berghaus
G
G
D000328:Adult; D002318:Cardiovascular Diseases / Q000209:etiology; D004958:Estradiol / Q000097:blood; D005260:Female; D005342:Fibrinolysis; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D007044:Hysterectomy / Q000009:adverse effects*; D008875:Middle Aged; D010053:Ovary / Q000502:physiology*; D017395:Plasminogen Activator Inhibitor 1 / Q000378:metabolism; D017697:Premenopause; D012307:Risk Factors; D012712:Serum Globulins / Q000378:metabolism; D010959:Tissue Plasminogen Activator / Q000378:metabolism
D017395:Plasminogen Activator Inhibitor 1; D012712:Serum Globulins; D004958:Estradiol; D005640:Follicle Stimulating Hormone; D010959:Tissue Plasminogen Activator